Pharmacotherapy in sickle cell disease—state of the art and future prospects. (abre una nueva ventana)

Hankins J, Aygun B.

Fuente‎: Br J Haematol 2009;145(3):296-308.

Indexado en‎: PubMed 19222472

DOI‎: 10.1111/j.1365-2141.2009.07602.x

https://www.ncbi.nlm.nih.gov/pubmed/19222472 (abre una nueva ventana)

Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. (abre una nueva ventana)

Hankins JS, Ware RE, Rogers ZR, Wynn LW, Lane PA, Scott JP, Wang WC.

Fuente‎: Blood 2005;106(7):2269-75.

Indexado en‎: PubMed 16172253

DOI‎: 10.1182/Blood-2004-12-4973

https://www.ncbi.nlm.nih.gov/pubmed/16172253 (abre una nueva ventana)

Hydroxyurea dose escalation for sickle cell anemia in sub-Saharan Africa. (abre una nueva ventana)

John CC, Opoka RO, Latham TS, Hume HA, Nabaggala C, Kasirye P, Ndugwa CM, Lane A, Ware RE

Fuente‎: N Engl J Med 2020;382(26):2524-33.

Indexado en‎: PubMed 32579813

DOI‎: 10.1056/NEJMoa2000146

https://www.ncbi.nlm.nih.gov/pubmed/32579813 (abre una nueva ventana)

The effect of hydroxcarbamide therapy on survival of children with sickle cell disease. (abre una nueva ventana)

Lobo CL, Pinto JF, Nascimento EM, Moura PG, Cardoso GP, Hankins JS.

Fuente‎: Br J Haematol 2013;161(6):852-60.

Indexado en‎: PubMed 23590693

DOI‎: 10.1111/bjh.12323

https://www.ncbi.nlm.nih.gov/pubmed/23590693 (abre una nueva ventana)

Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries. (abre una nueva ventana)

Mulaku M, Opiyo N, Karumbi J, Kitonyi G, Thoithi G, English M.

Fuente‎: Arch Dis Child 2013;98(11):908-14.

Indexado en‎: PubMed 23995076

DOI‎: 10.1136/archdischild-2012-302387

https://www.ncbi.nlm.nih.gov/pubmed/23995076 (abre una nueva ventana)

Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. (abre una nueva ventana)

Strouse JJ, Lanzkron S, Beach MC, Haywood C, Park H, Witkop C, Wilson RF, Bass EB, Segal JB.

Fuente‎: Pediatrics 2008;122(6):1332-42.

Indexado en‎: PubMed 19047254

DOI‎: 10.1542/peds.2008-0441

https://www.ncbi.nlm.nih.gov/pubmed/19047254 (abre una nueva ventana)

Impact of hydroxyurea on clinical events in the BABY HUG trial. (abre una nueva ventana)

Thornburg CD, Files BA, Luo Z, Miller ST, Kalpatthi R, Iyer R, Seaman P, Lebensburger J, Alvarez O, Thompson B, Ware RE, Wang WC; BABY HUG Investigators.

Fuente‎: Blood 2012;120(22):4304-10.

Indexado en‎: PubMed 22915643

DOI‎: 10.1182/blood-2012-03-419879

https://www.ncbi.nlm.nih.gov/pubmed/22915643 (abre una nueva ventana)

Hydroxyurea for children with sickle cell anemia in sub-Saharan Africa. (abre una nueva ventana)

Tshilolo L, Tomlinson G, Williams TN, Santos B, Olupot-Olupot P, Lane A, Aygun B, Stuber SE, Latham TS, McGann PT, Ware RE; REACH Investigators

Fuente‎: N Engl J Med 2019;380(2):121-31.

Indexado en‎: PubMed 30501550

DOI‎: 10.1056/NEJMoa1813598

https://www.ncbi.nlm.nih.gov/pubmed/30501550 (abre una nueva ventana)

Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study. (abre una nueva ventana)

Wang WC, Helms RW, Lynn HS, Redding-Lallinger R, Gee BE, Ohene-Frempong K, Smith-Whitley K, Waclawiw MA, Vichinsky EP, Styles LA, Ware RE, Kinney TR.

Fuente‎: J Pediatr 2002;140(2):225-9.

Indexado en‎: PubMed 11865275

DOI‎: 10.1067/mpd.2002.121383

https://www.ncbi.nlm.nih.gov/pubmed/11865275 (abre una nueva ventana)

Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. (abre una nueva ventana)

Wang WC, Oyeku SO, Luo Z, Boulet SL, Miller ST, Casella JF, Fish B, Thompson BW, Grosse SD; BABY HUG Investigators.

Fuente‎: Pediatrics 2013;132(4):677-83.

Indexado en‎: PubMed 23999955

DOI‎: 10.1542/peds.2013-0333

https://www.ncbi.nlm.nih.gov/pubmed/23999955 (abre una nueva ventana)

Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). (abre una nueva ventana)

Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, Rana S, Thornburg CD, Rogers ZR, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik SA, Howard TH, Wynn LW, Kutlar A, Armstrong FD, Files BA, Goldsmith JC, Waclawiw MA, Huang X, Thompson BW; for the BABY HUG investigators.

Fuente‎: Lancet 2011;377(9778):1663-72.

Indexado en‎: PubMed 21571150

DOI‎: 10.1016/S0140-6736(11)60355-3

https://www.ncbi.nlm.nih.gov/pubmed/21571150 (abre una nueva ventana)

Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. (abre una nueva ventana)

Ware RE, Davis BR, Schultz WH, Brown RC, Aygun B, Sarnaik S, Odame I, Fuh B, George A, Owen W, Luchtman-Jones L, Rogers ZR, Hilliard L, Gauger C, Piccone C, Lee MT, Kwiatkowski JL, Jackson S, Miller ST, Roberts C, Heeney MM, Kalfa TA, Nelson S, Imran H, Nottage K, Alvarez O, Rhodes M, Thompson AA, Rothman JA, Helton KJ, Roberts D, Coleman J, Bonner MJ, Kutlar A, Patel N, Wood J, Piller L, Wei P, Luden J, Mortier NA, Stuber SE, Luban NL, Cohen AR, Pressel S, Adams RJ.

Fuente‎: Lancet 2016;387(10019):661-70.

Indexado en‎: PubMed 26670617

https://www.ncbi.nlm.nih.gov/pubmed/26670617 (abre una nueva ventana)

How I use hydroxyurea to treat young patients with sickle cell anemia. (abre una nueva ventana)

Ware RE.

Fuente‎: Blood 2010;115(26):5300-11.

Indexado en‎: PubMed 20223921

DOI‎: 10.1182/blood-2009-04-146852

https://www.ncbi.nlm.nih.gov/pubmed/20223921 (abre una nueva ventana)

Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. (abre una nueva ventana)

Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE.

Fuente‎: Blood 2004;103(6):2039-45.

Indexado en‎: PubMed 14630791

DOI‎: 10.1182/blood-2003-07-2475

https://www.ncbi.nlm.nih.gov/pubmed/14630791 (abre una nueva ventana)

Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. (abre una nueva ventana)

Hirst C, Owusu-Ofori S.

Fuente‎: Cochrane Database Syst Rev 2012;(9):CD003427.

Indexado en‎: PubMed 22972063

DOI‎: 10.1002/14651858.CD003427.pub2

https://www.ncbi.nlm.nih.gov/pubmed/22972063 (abre una nueva ventana)

Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. (abre una nueva ventana)

Howard J, Ataga KI, Brown RC, Achebe M, Nduba V, El-Beshlawy A, Hassab H, Agodoa I, Tonda M, Gray S, Lehrer-Graiwer J, Vichinsky E

Fuente‎: Lancet Haematol 2021;8(5):e323-33.

Indexado en‎: PubMed 33838113

DOI‎: 10.1016/S2352-3026(21)00059-4

https://www.ncbi.nlm.nih.gov/pubmed/33838113 (abre una nueva ventana)

Sickle cell disease. (abre una nueva ventana)

Meremikwu MM, Okomo U.

Fuente‎: BMJ Clin Evid 2011;02:2402.

Indexado en‎: PubMed 21718552

https://www.ncbi.nlm.nih.gov/pubmed/21718552 (abre una nueva ventana)

A phase 3 trial of l-glutamine in sickle cell disease. (abre una nueva ventana)

Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP

Fuente‎: N Engl J Med 2018;379(3):226-35.

Indexado en‎: PubMed 30021096

DOI‎: 10.1056/NEJMoa1715971

https://www.ncbi.nlm.nih.gov/pubmed/30021096 (abre una nueva ventana)

Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa. (abre una nueva ventana)

Olupot-Olupot P, Tomlinson G, Williams TN, Tshilolo L, Santos B, Smart LR, McElhinney K, Howard TA, Aygun B, Stuber SE, Lane A, Latham TS, Ware RE

Fuente‎: Blood. 2023 23;141(12):1402-10.

Indexado en‎: PubMed 36375125

DOI‎: 10.1182/blood.2022017051

https://pubmed.ncbi.nlm.nih.gov/36375125/ (abre una nueva ventana)

Malaria chemoprophylaxis in sickle cell disease. (abre una nueva ventana)

Oniyangi O, Omari AA.

Fuente‎: Cochrane Database Syst Rev 2006;(4):CD003489.

Indexado en‎: PubMed 17054173

DOI‎: 10.1002/14651858.CD003489.pub2

https://www.ncbi.nlm.nih.gov/pubmed/17054173 (abre una nueva ventana)